Featured Research

Learn about Rhythm's latest publications and conference presentations, including a poster describing the study design of the phase 2 DAYBREAK trial, which will evaluate setmelanotide for weight loss and hunger reduction in patients with a genetic variant associated with the melanocortin-4 receptor (MC4R) pathway.


Continue expanding your understanding of these disease states with the latest resources available from Rhythm Pharmaceuticals related to rare genetic diseases of obesity.

Explore Now


  1. Huvenne H, et al. Obes Facts. 2016;9(3):158-173.
  2. da Fonseca ACP, et al. J Diabetes Complications. 2017;31(10):1549-1561.
  3. Heymsfield SB, et al. Obesity (Silver Spring). 2014;22(suppl 1):S1-S17.

You are now leaving Rhythm Medical Gateway. Links to all outside websites are provided as a convenience to our visitors and do not imply a recommendation by Rhythm Pharmaceuticals.

The information contained on this site is intended for US health care professionals only